Meningococcal Vaccines Market Report 2026

The meningococcal vaccines market size has grown strongly in recent years. It will grow from $4.26 billion in 2025 to $4.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to introduction of meningococcal conjugate vaccines, rising incidence of meningitis outbreaks, government immunization campaigns, growing pediatric vaccination coverage, increased public health funding.

The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $6.58 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to advancements in vaccine technology, expansion of global immunization programs, increasing awareness of meningococcal disease, strategic partnerships and collaborations, growth in adolescent and young adult vaccination initiatives. Major trends in the forecast period include expansion of pediatric vaccination programs, development of broad-spectrum meningococcal vaccines, increased government immunization initiatives, rising awareness of meningococcal disease prevention, growth of school and college vaccination campaigns.

Rising healthcare spending is expected to drive growth in the meningococcal vaccine market in the coming years. Healthcare encompasses residential care institutions, nursing facilities, and intermediate care centers for individuals with mental illnesses or intellectual disabilities. The higher cost of newer vaccine generations compared to older ones has raised discussions on whether the benefits justify the prices, making it increasingly important to assess the full social and economic advantages of vaccination. For instance, in April 2025, according to an article published by the American Medical Association, a US-based professional association, health spending in the U.S. increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per capita - a significant rise from the 4.6% increase in 2022. Therefore, rising healthcare expenditure is fueling the growth of the meningococcal vaccine market.

Leading companies in the meningococcal vaccine market are developing new vaccines that provide protection against multiple serogroups to enhance market profitability. Meningococcal vaccines are designed to prevent infections caused by specific serogroups of the bacterium Neisseria meningitidis. For example, in October 2023, Pfizer Inc., a US-based pharmaceutical company, received FDA approval for PENBRAYA. This vaccine provides extensive serogroup coverage, protecting against groups A, B, C, W, and Y. FDA approval was based on robust Phase 2 and 3 trial data, demonstrating non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, alongside a favorable safety profile. In September 2022, Pfizer announced positive outcomes from a Phase 3 trial comparing PENBRAYA with existing licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.

In September 2023, Biovac Institute, a South Africa-based vaccine manufacturer, partnered with EuBiologics Co., Ltd., to facilitate technology transfer for meningitis vaccines. The collaboration aims to strengthen local production capabilities, improve access to high-quality meningitis vaccines, and support regional immunization programs while fostering innovation and growth in vaccine development. EuBiologics Co., Ltd. is a South Korea-based biopharmaceutical company specializing in research, development, and commercialization of vaccines for infectious diseases.

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S.

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the meningococcal vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the meningococcal vaccines market by increasing the cost of imported vaccine components and raw materials, leading to higher production expenses. This impact is most pronounced in regions such as Asia-Pacific and Europe, where large volumes of vaccines and biologics are manufactured and distributed. Segments like meningococcal conjugate vaccines and polysaccharide vaccines face significant cost pressures, while public health programs may experience delays in procurement. However, tariffs have also encouraged local manufacturing initiatives and supply chain diversification, which could foster long-term market resilience and innovation.

The meningococcal vaccines market research report is one of a series of new reports that provides meningococcal vaccines market statistics, including meningococcal vaccines industry global market size, regional shares, competitors with a meningococcal vaccines market share, detailed meningococcal vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal vaccines industry. This meningococcal vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Meningococcal vaccinations are designed to protect against Neisseria meningitidis, the bacteria that cause meningitis and bloodstream infections. These vaccines enable the immune system to recognize and combat the bacteria before illness develops. They are primarily used to prevent severe, potentially life-threatening meningococcal disease, particularly in high-risk groups such as adolescents, college students, and travelers.

The main types of meningococcal vaccines include meningococcal conjugate vaccines, polysaccharide vaccines, and subcapsular vaccines. Meningococcal conjugate vaccines consist of a polysaccharide antigen linked (conjugated) to a carrier molecule. The vaccines cover different serotypes, including Men ACWY, Men B/Bc, and Men C, and are administered to various age groups such as infants, children, adolescents, young adults, and adults. These vaccines are distributed through pharmacies, community clinics, public health agencies, and other channels, and are used by hospitals, research institutions, and academic centers.

The meningococcal vaccines market consists of sales of conjugate vaccines, combination vaccines, serogroup B vaccine products, and other types. Values in this market are ‘pharmaceuticals’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.